Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Sells $175,279.92 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 23,124 shares of the stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total value of $175,279.92. Following the sale, the chief financial officer now owns 1,231,055 shares of the company’s stock, valued at approximately $9,331,396.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Michael Secora also recently made the following trade(s):

• On Wednesday, March 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $11.03, for a total value of $275,750.00.
• On Tuesday, February 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.86, for a total value of $246,500.00.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $7.35 on Friday. The business has a fifty day moving average of $10.73 and a 200 day moving average of $9.09. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.54 and a 1 year high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. The company had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RXRX. Needham & Company LLC reiterated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. TD Cowen started coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating for the company. Finally, KeyCorp raised their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $12.75.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Azzad Asset Management Inc. ADV acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth about $161,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in Recursion Pharmaceuticals by 12.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock worth $103,317,000 after purchasing an additional 1,159,023 shares during the period. Oxinas Partners Wealth Management LLC acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth about $122,000. TB Alternative Assets Ltd. acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth about $706,000. Finally, Wedmont Private Capital grew its position in Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after purchasing an additional 2,000 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.